Categories: BioTechDesign
Inthera Bioscience is an emerging Swiss biotechnology company that develops innovative and highly effective therapies against currently incurable cancers. The company is tackling “undruggable” targets with innovative chemistry for the design of small molecule inhibitors of intracellular protein-protein interactions. The most advanced of these first-in-class therapeutics, a modulator of dysregulated transcription, is currently progressing towards clinical stage.
Investors 2
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.06.2018 | Series A | $5.48M | - |
| 31.05.2017 | Series A | $10.91M | - |
Mentions in press and media 6
| Date | Title | Description |
| 26.06.2018 | Inthera Bioscience Raises €4.7M Second Tranche of €9.6M Series A | Inthera Bioscience AG, a Wädenswil, Switzerland-based pre-clinical stage oncology company targeting the inhibition of protein-protein interactions with innovative small molecule chemistry, secured the second €4.7m tranche of its Series A fi... |
| 26.06.2018 | Inthera Bioscience secures €4.7 million in series A financing | |
| 02.06.2017 | Inthera Bioscience Raises CHF 10.5 Million in Series A Financing Round | |
| 31.05.2017 | Inthera Bioscience Raises CHF10.5M in Series A Financing Round | Inthera Bioscience, a Zurich, Switzerland-based biopharmaceutical company developing targeted small molecule therapies for solid tumors, closed a CHF10.5m (€9.6m) Series A financing.
The round was led by Merck Ventures, with equal contribut... |
| 15.12.2015 | Inthera Bioscience Raises $3.7M in Seed Funding | Inthera Bioscience, a Zürich, Switzerland-based biopharmaceutical company focused on the development of small molecule therapies for solid tumors, raised $3.7m (€3.4m) seed funding round.
The round was led by MS Ventures, with equal partici... |
| 14.12.2015 | Inthera Bioscience raises EUR 3.4 million in seed financing round | |
Reviews 0
